Hologic wins Novation deal for osteoporosis testing:
This article was originally published in Clinica
Hologic has signed a sole source, three-year agreement with Novation for its osteoporosis testing technology. Hologic, of Bedford, Massachusetts, says the deal represents the largest customer endorsement of its technology to date. Irving, Texas-based Novation manages over $14 billion in annual purchases for members of national healthcare alliances VHA and UHC.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.